Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Open-label Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies
jRCT2080224739Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imaradenant in Non-hematologic malignancy and metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD4635, Pharmacokinetics of AZD4635 and 1 more. Started Jun 2019; status: completed.
02
Drugs
imaradenant
03
Conditions
Non-hematologic malignancymetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2080224739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224739.